The ten-pneumococcal conjugate vaccine (PCV10) was introduced into the national immunization program for childhood vaccination schedules by the Brazilian Health Public Service in March 2010. The aim of this study was to compare Streptococcus pneumoniae serotype distribution, antibiotic resistance patterns, and potential coverage before (January 2006-June 2010) and after (July 2010-September 2012) PCV10 introduction. The incidence of invasive pneumococcal disease (IPD), patient demographics, and disease characteristics were recorded. This study was conducted at the University Hospital of Sao Paulo University in Brazil from January 2006 to September 2012. Serotyping was performed using multiplex PCR typing, and antimicrobial sensitivity by Clinical and Laboratory Standards Institute (CLSI). A total of 259 S. pneumoniae strains were isolated from patients with IPD. The ages of the patients ranged from 3 months to 95 years old. The strains were isolated from cerebrospinal fluid, pleural fluid, and blood. The incidence of IPD among patients at HU-USP changed after the introduction of PCV10. The overall incidence of IPD was 3.42 cases per 1000 admissions in the vaccine pre-implementation period and of 2.99 cases per 1000 admissions in the vaccine post-implementation period. The incidence of IPD among children<2 y.o. attended at HU-USP changed significantly after the introduction of PCV10, from 20.30 to 3.97 of incidence. The incidence of PCV10-serotypes decrease from 16.47 to 0.44 in the same age, before and after PC10 implementation, respectively. Moreover, it was possible to realize the sensitivity to penicillin among isolates increased significantly in the post-vaccine period. Data from this study suggest that PCV10 contributed to decrease with PID rate among children less than 2 y.o. The resistance rate among pneumococcal isolates also could be observed since serotypes with greater resistance to beta lactam antibiotics were not easily isolated after vaccination.
Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation 
Introduction
Streptococcus pneumoniae is the major cause of communityacquired pneumonia, and it has been estimated that 13.8 million pneumonia cases occur worldwide each year, causing 90% of all pneumococcus-related deaths [1] .
Pneumococcal disease accounted for 34,217 hospitalizations from 2004 to 2006 in the Brazilian National Health System. Pneumococcal pneumonia accounts for 64.8% of these hospitalizations. Although the highest rates of this disease occur in children under * Corresponding author at: University Hospital-USP, Brazil. Tel.: +55 1130919303; fax: +55 1130919470.
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one year of age, the highest hospital case fatality rates occur among the elderly, primarily resulting from sepsis and meningitis [2] . Ninety-three different capsular types of S. pneumoniae have been detected to date. Despite this variety, only a select group of serotypes are responsible for the majority of invasive disease, particularly in children. Importantly, the prevalence of serotypes may vary according to demographic region and the period of study [3] . Few serotypes demonstrate penicillin resistance, and these serotypes are globally assigned to the 6B, 6A, 9V, 14, 15A, 19F, 23F, and 19A serotypes, collectively called the "pediatric serotypes".
Today, the 23-valent polysaccharide vaccine is used to vaccinate at-risk adults and the elderly. Unfortunately, immunization with PPV has recently been found to be largely unsuccessful in the elderly population. Conjugate vaccines have been designed to improve efficacy in children <2 years of age [4] . PCV7 was first recommended for use in the United States in the year 2000. This vaccine contains the capsular polysaccharide of seven serotypes conjugated to CRM197 (4, 6B, 9V, 14, 18C, 19F, and 23F), which were selected because they caused the majority of invasive disease in the US at that time [5] . Additionally, these serotypes are also associated with high antibiotic resistance [6, 7] .
Several authors report a sharp, sudden decline in IPD caused by vaccine serotypes. This decrease occurs rapidly after the introduction of vaccination programs, both in the vaccinated children and in all age groups [8] [9] [10] . Following the introduction of PCV7 in the US, a shift in the prevalent serotypes circulating in the population and causing disease (termed serotype replacement) was observed [4] .
Serotyping is required to monitor epidemiological trends following the introduction of serotype-specific polysaccharide conjugate vaccines, which include serotypes commonly encountered in carriage and disease. The introduction of these vaccines has led to increased monitoring of the serotypes that cause invasive disease. Additionally, there are reports of increases in disease incidences caused by non-PCV7 serotypes. Thus, new conjugate vaccines PCV10 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, and 7F) and PCV13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, 7F, 3, 6A, and 19A) have been introduced to replace PCV7 and expand protective coverage. Continuous surveillance is crucial to monitor vaccine efficacy and serotype replacement in different geographical regions [11] .
In Brazil, PCV10 was introduced into the national immunization program for the childhood vaccination schedule by the Brazilian Health Public Service in March 2010.The aim of this study was to compare the incidence of IPD at our hospital, S. pneumoniae serotype distribution and antibiotic resistance patterns before (January 2006-June 2010) and after (July 2010-September 2012) PCV10 introduction.
Materials and methods
The ten-pneumococcal conjugate vaccine (PCV10) was introduced into the national immunization program for the childhood vaccination schedule by the Brazilian Health Public Service in March 2010. The vaccination schedule used in Brazil is three doses in the first six months of life, with a booster dose at 12-15 months of age. Time periods encompassing pre-and post-implementation of PCV10 (January 2006 to June 2010 and July 2010 to September 2012, respectively) were examined.
This study was conducted at the University Hospital of Sao Paulo University (HU-USP) in Brazil from January 2006 to September 2012. This hospital attends people from Butantã, a region of São Paulo city with a population of approximately 408,000. The patients attended at the HU-USP belong to the Brazilian Health Public Service. The patients were stratified at least three age groups: children (<2 y.o.), children (from 2 to <15 y.o.) and adult (>15 y.o.). During the study period, were admitted to intensive care unit and the ward 3946 and 2264 children (<2 y.o.); 9245 and 5168 children (from 2 to <15 y.o.); 38,780 and 18,637 adults (>15 y.o.) before and after PCV10 introduction, respectively. A total of 259 patients were diagnosed with invasive pneumococcal disease and S. pneumoniae strains were isolated from cerebrospinal fluid (36), pleural fluid (24) , and blood (199). The patients' ages ranged from 3 months to 95 years old.
All pneumococcal strains were isolated from clinical specimens according to Garcia and Isenberg [12] . Identification of strains was performed in the Clinical Laboratory of HU-USP. Isolates were cultured on blood agar medium with 5%CO 2 at 35 • C and identified using conventional methods, including bile solubility testing, optochin sensitivity, and Vitek2 (BioMerieux ® , France).
All pneumococcal isolates were serotyped using sequential multiplex PCR typing [13, 14] . Briefly, a schematic sequence-based system of six multiplex PCRs was used in a sequence order based upon Active Bacterial Core surveillance (ABCs) serotype distribution during 2002 and 2003.The system was revised for optimal targeting of prevalent serotypes in Latin America to reliably deduce specific pneumococcal serotypes.
Antibiotic susceptibility testing was done following CLSI guidelines [15] . All of the isolates were examined for antibiotic susceptibility against clindamycin, chloramphenicol, erythromycin, rifampicin, tetracycline, trimethoprim-sulfamethoxazole, and levofloxacin by the disk-diffusion method (Oxoid, Cambridge, UK). Penicillin and ceftriaxone resistance were verified using the Etest (AB BIODISK, Solna, Sweden). The breakpoints used for interpretation were those recommended by the CLSI in 2012.
Statistical analyses were performed using Fisher's exact test as appropriate. We considered p < 0.05 to be significant. All p values are two sided. Statistical analyses were performed with Statistica (version 6.1 StatSoft, Tulsa, OK, USA).
Results
During the study period, the HU-USP clinical laboratory recovered 259 S. pneumoniae isolates from 259 IPD patients: 178 during the pre-implementation PCV10 period and 81 during the postimplementation period. The incidence of IPD among patients at HU-USP changed after the introduction of PCV10. A significantly decline in overall IPD incidence (from 20.3 to 3.97 cases/1,000 people) was observed in children with <2 years of age (p = 0.0012) after introduction of PCV10. A decline but non-significant was seen in children from 2 to <15 years of age. IPD incidence rates remained unchanged in people >15 y.o. (from 1.72 to 3.16 cases/1000 people, p = 0.4149). Comorbidities such as HIV, alcoholism, and cirrhosis did not appear to influence the development of IPD. Among the cases, 11% (20/178) had comorbidities in the pre-implementation period, compared with 14% (11/81) in the post-implementation period (p > 0.05). In the pre-vaccination period, the rates of isolation of strains relative to age were as follows: 44.4% (<2 y.o.), 11.2% (2-4 y.o.), 6.2% (5-14 y.o.), 24.7% (15-60 y.o.), and 12,9% (>60 y.o.). The most significant decrease in IPD occurred in children <2 y.o. (p < 0.0012). After PCV10 introduction, 11% of the strains were isolated from children <2 y.o. and 57% from adults (15-60 y.o.) (Table 1) . Culture-confirmed cases of S. pneumoniae from IPD decreased by 46% overall after PCV10 introduction, confirmed cases in children <2 y.o. decreased by 89% (Table 1) .
After introduction of PCV10, a clear reduction in IPD for those serotypes contained in the vaccine was observed (Fig. 1) . After PCV10 vaccination, it is possible to observe a downward trend in the incidence of PCV10 serotypes, a significant reduction occurred in the age group of 2 years old (from 16.47 to 0.44 cases/1000 people (p < 0.0002). However, no significant increase was observed in the adults (people >15 y.o.). Non-PCV 10 serotypes incidence rates remained unchanged in all age group (Table 1) .
In the period preceding PCV10 introduction, the most frequently isolated serotypes among patients of all ages were serotypes 14 (0.92 cases/1000 people), 5 (0.45 cases/1000 people), 6B (0.31 cases/1000 people), 12F (0.34 cases/1000 people), and 1 (0.17 cases/1000 people). After the introduction of the vaccine, serotype 7F was the most frequently isolated (0.50 cases/1,000 people), followed by 8 (0.43 cases/1,000 people), 12F (0.40 cases/1,000 people), and 3 (0.37 cases/1000 people). Among children <2 y.o. with IPD, 79% were infected with S. pneumoniae belonging to a vaccine serotype during the pre-vaccination period. After PCV10 introduction, 11% of children <2 y.o. were infected with one vaccine 
Table 2
Pneumococcal serotype distribution in children <2, children 2 to <15, and adults ≥15 years old. serotype, 14. Data on the serotype distribution of IPD in different age groups are summarized in Table 2 .
A total of 259 S. pneumoniae strains were examined for antibiotic susceptibility. Among the pre-vaccination and post-vaccination strains, no trend in increasing antimicrobial susceptibility was observed for clindamycin, chloramphenicol, erythromycin, rifampicin, tetracycline, or levofloxacin (p > 0.05), but susceptibility to trimethoprim-sulfamethoxazole increased from 31 to 68% (group <15 y.o.) and 64 to 88% (group >15 y.o.) after introduction of PCV10 (p < 0.002). The sensitivity to penicillin and ceftriaxone increased significantly in the post-vaccine period. In all age group the number of strains isolated with penicillin MIC <0.06 g/ml increased after vaccination period, from 47.7 to 77.3% (<15 y.o; p = 0.04) and from 80.6 to 94.8% (>15 y.o.; p = 0.03). The sensitivity of pneumococci to ceftriaxone increased significantly in pediatric patients in the post-vaccine period. The percentage of pneumococci with MIC less than 0.05 g/ml increased in the post-vaccination period, from 71.6% to 95.5% (< 15 y.o.; p = 0.02). No significance was observed among isolates from adults (<15 y.o.) (Tables 3 and 4 ).
Discussion
The S. pneumoniae is a predominant cause of communityacquired pneumonia, exacerbation of chronic bronchitis, meningitis, sinusitis, and bacteremia in both developed and developing countries. The WHO estimates that out of the approximately 8.8 million global annual deaths among children <5 years in 2008, 476,000 (333,000-529,000) were caused by pneumococcal a Vaccination periods: pre-vaccination period, January 2006-June 2010; post-vaccination period, July 2010-September 2012. MIC: minimal inhibitory concentration. Statistical analyses were performed using Fisher's exact test as appropriate. We considered p < 0.05 to be significant. All p values are two sided. Statistical analyses were performed with Statistica (version 6.1 StatSoft, Tulsa, OK, USA).
Table 4
Ceftriaxone susceptibility profile before and after introduction of PCV10.
MIC (g/ml)
<15 years old >15 years old infections. In developing countries, case-fatality rates among younger infants may reach 20% for pneumococcal septicemia and 50% for meningitis [16] . A recent review of randomized, controlled trials of PCV7 found a vaccine efficacy (VE) against invasive pneumococcal disease of 71%. Based on immunogenicity data, PCV10 shows a comparable VE for serotypes contained in the vaccine [16] .
In the present study, the incidence of IPD was reduced by 80% in children younger than two years after the introduction of PCV10In the period preceding vaccine introduction, serotype 14 was the most common in this age group, followed by 6B. After PCV10 was introduced in Brazil by the Brazilian Health Public Service, there was a decrease in the vaccine serotypes isolated from patients with IPD who were attended at HU-USP. Even in other age groups (>2y.o.), it is possible to observe a decreasing trend in the incidence of PCV10 serotypes. However, no significant increase was observed in the overall incidence of non-PCV10 serotype IPD. It is interesting to highlight that the incidence of serotype 19A in the period post-vaccination did not increase as showed by other studies [17, 18] . In pediatric patients (<15 y.o.) this serotype was identified in five cases in the pre-vaccination period and only one in the period following vaccination. In adults (>15 y.o.), two and one cases were identified in the pre-vaccination and post-vaccination period, respectively.
Here, it is interesting to note that the shift in pneumococcal serotypes isolated was so pronounced that the order of the sequential multiplex PCR array had to be rearranged. The most strains isolated prior to the vaccination period were typed using sequential reaction number one, in which 46% of strains were typed. However, the majority of isolates after the vaccination period (50%) were typed using sequential multiplex PCR typing number three, followed by number four.
From 1993 to 1999 in Brazil, 63 serotypes were identified among 4,858 cases of invasive pneumococcal disease [18] . Eleven capsular serotypes were responsible for 86% of these cases. The serotypes 14 (33%), 1 (12%), 5 (11%), 6A/6B (11%), 23F (4.%), and 19A (4%) displayed a strong association with pneumonia [18] . A study conducted in Latin America from 2000 to 2005 confirms that the most common serotypes in Brazil were 14 (49%), 1 (13%), and 6B (8%) [19] . In other studies, similar serotype distributions were observed [20, 21] .
Despite the use of antimicrobial treatments, the rates of pneumococcal resistance to non-meningeal infections are low. Additionally, treatment failure for pneumococcal pneumonia has not previously been reported. Data from this study suggest that PCV10 contributed to the decrease in the resistance rate among pneumococcal isolates because serotypes of strains with higher resistance rates to beta lactam antibiotics were poorly isolated after vaccination. Similar results are also observed in countries that introduced PCV7 in the 2000s. Further, it was found that the rate of resistance to penicillin significantly declined in these studies [22] [23] [24] .
The number of patients in our study represents only a small portion of vaccinated Brazilian children, and the study period was too short to enable us to draw firm conclusions about changes in serotype-specific incidence. However, these data are the first from Brazil examining the effects of PCV10 on IPD. Moreover, these data are useful because the epidemiology of IPD in developing countries differs from that in other parts of the world.
The rapid introduction of PCVs in developing countries has much support. The incidence of disease in these areas should be monitored following the introduction of vaccines to investigate their effects on disease prevalence. According to the WHO, the impact of PCV should be carefully monitored as part of a routine sentinel surveillance system. Available evidence does not suggest that serotype replacement is an impediment to PCV introduction [25] . However, the occurrence and magnitude of serotype replacement should be monitored through carefully conducted surveillance studies, including in low-income settings [16] .
Conclusion
In the present study, the incidence of vaccine serotypes decreased from 2.38 to 1.03 following PCV10 introduction. A significantly decline in overall IPD incidence (from 20.3 to 3.97 cases/1000 people) was observed in children with <2 years of age (p = 0.0012) after introduction of PCV10. Data from this study suggest that PCV10 contributed to the decrease in the resistance rate among pneumococcal isolates because serotypes of strains with higher resistance rates to beta lactam antibiotics were poorly isolated after vaccination.
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